Ignite Creation Date:
2025-12-24 @ 5:50 PM
Ignite Modification Date:
2026-02-22 @ 3:57 PM
Study NCT ID:
NCT02856568
Status:
WITHDRAWN
Last Update Posted:
2017-05-30
First Post:
2016-07-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Sponsor:
Mayo Clinic
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-Resectable Cholangiocarcinoma | View |
| None | Recurrent Cholangiocarcinoma | View |
| None | Stage III Extrahepatic Bile Duct Cancer | View |
| None | Stage III Intrahepatic Cholangiocarcinoma | View |
| None | Stage IIIA Hilar Cholangiocarcinoma | View |
| None | Stage IIIB Hilar Cholangiocarcinoma | View |
| None | Stage IVA Extrahepatic Bile Duct Cancer | View |
| None | Stage IVA Hilar Cholangiocarcinoma | View |
| None | Stage IVA Intrahepatic Cholangiocarcinoma | View |
| None | Stage IVB Extrahepatic Bile Duct Cancer | View |
| None | Stage IVB Hilar Cholangiocarcinoma | View |
| None | Stage IVB Intrahepatic Cholangiocarcinoma | View |
| None | Unresectable Extrahepatic Bile Duct Carcinoma | View |
Keywords: